Scancell Limited – Trademark Portfolio
Entity Type: 99
Scancell Limited holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include GLYMAB, AVIDIMAB, MODITOPE, SCANCELL, and IMMUNOBODY. The owner is based in Oxford.
Sanders Road Oxford Science Park
Bellhouse Building
Oxford OX44GD , GB
Showing of trademarks Trademarks
Trademark Classifications
Scancell Limited's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Scancell Limited have?
Scancell Limited has 8 U.S. trademarks filed with the USPTO. Of these, 5 registered, 3 cancelled.
What trademark classes does Scancell Limited file in?
Scancell Limited files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Scancell Limited's most well-known trademarks?
Scancell Limited's registered trademark portfolio includes well-known marks such as GLYMAB, AVIDIMAB, MODITOPE, SCANCELL, and IMMUNOBODY. These are among 5 currently registered trademarks in the portfolio.
What is Scancell Limited's trademark registration success rate?
Scancell Limited has a 63% trademark registration rate, with 5 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.